| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18760 R79788 |
Moore (Topiramate) (Mixed indications) (Controls exposed to LTG), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.92 [0.62;1.36] C excluded (control group) |
37/172 215/934 | 252 | 172 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18761 R79792 |
Moore (Topiramate) (Mixed indications) (Controls unexposed, general pop), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Matched | 1.09 [0.73;1.63] | 37/172 253/1,720 | 290 | 172 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12715 R47970 |
Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.07 [1.22;3.50] C excluded (control group) |
16/471 133/7,950 | 149 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12716 R47973 |
Bjørk (Topiramate) (Controls unexposed NOS) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
2.29 [1.40;3.74] excluded (control group) |
16/471 68,295/4,463,879 | 68,311 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12718 R47979 |
Bjørk (Topiramate) (Controls unexposed, sick) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up topiramate 5.7 (2.9-9.1) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.68 [1.01;2.79] C | 16/471 443/21,634 | 459 | 471 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8613 R28740 |
Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Disorders of psychological development (F80–F89) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 0.80 [0.30;2.60] | 3/477 10,010/1,710,441 | 10,013 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8554 R28463 |
Arkilo (Topiramate), 2015 | Abnormal development (At 2 years of age, assessed by developmental specialists) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.87 [0.09;91.05] C | 0/2 2/24 | 2 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.25 [0.92;1.69] | 10,764 | 1,122 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Mixed indications) (Controls unexposed, general pop; 2: Topiramate) (Controls unexposed, sick) (Mixed indications; 3: Topiramate) (Controls unexposed, NOS) (Mixed indications; 4: Topiramate;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 12715, 12716, 18760